Related Experiment Video
Updated: Aug 31, 2026

Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome
Published on: December 12, 2025
New methods advance treatment for respiratory distress syndrome
1Perinatology Center, New York Presbyterian Hospital, 525 East 68th St., New York, NY 10021, USA.
Abstract:
The past 20 years of hard labor in neonatal respiratory distress have resulted in several important advances arising from our understanding of lung chemistry and physiology. Our knowledge of surfactant chemistry has enabled us to identify infants at high risk for developing neonatal distress due to surfactant deficiency, reducing this risk with antenatal corticosteroid treatment, and improving the neonatal outcome by means of administration of effective surfactant replacement. Recognition of the roles of oxygen toxicity and barotrauma in promoting lung injury has premitted the development of more effective means of assisted ventilation less likely to injure the lungs of severely ill infants with pulmonary failure. Nitric oxide has proven to be an effective pulmonary vasodilator and permits the successful treatment of patients with pulmonary hypertension who might previously have required an invasive surgical treatment to achieve a desirable clinical outcome.
Related Concept Videos
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Cardiopulmonary Resuscitation V: Advanced Airway Management Techniques
Mechanical Ventilation III: Noninvasive Ventilation
Noninvasive Positive-Pressure Ventilation (NIPPV)
Cardiopulmonary Resuscitation II: ACLS Airway Management
Acute Respiratory Failure-IV
Acute Respiratory Failure-III
